Previous 10 | Next 10 |
home / stock / asclf / asclf news
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. Beijing's BeiGene presented positive interim results from Phase III trial that compared its BTK candidate to AbbVie's Imbruv...
NiKang Therapeutics, a clinical stage Delaware biotech, raised $200 million in a Series C financing from US and China investors. Esco Lifesciences of Singapore, an Asia-based life sciences tools company, closed an over-subscribed $200 million Series A and crossover round. Suzhou's...
The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian ...
Adagene completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Antibe Therapeutics in a $100 million agreement. Junshi Biosciences and Eli Lilly announ...
DXY.cn, a China healthcare platform, raised $500 million in an E round. Zai Lab in-licensed China rights to a next-gen EGFR inhibitor aimed at cells expressing mutant EGFR variants from Boston's Cullinan Oncology in an agreement worth up to $233 million. Hutchison China MediTech a...
The FDA designates Fast Track designation to Gannex's, a unit of Ascletis Pharma ([[ASCLF]]) ASC42 for the treatment non-alcoholic steatohepatitis.ASC42 is an in-house developed,novel non-steroidal, selective, potent Farnesoid X Receptor agonist. For further detai...
HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million. Singapore's ASLAN Pharmaceuticals announced plans to develop ASLAN003, its next-gen dihydroorotate dehydrogenase inhibitor in autoimmune conditions, such as multiple sclerosis. ...
Deals and Financings Baidu (BIDU), one of China's major internet/AI companies, is talking with investors about raising $2 billion to fund a new China drug development and diagnostics company. It believes the $2 billion fundraising will take two years to complete. The new company plans to...
Galmed Pharmaceuticals (NASDAQ: GLMD ) anf Gannex Pharma, a wholly owned company of Ascletis Pharma Inc. ( OTCPK:ASCLF ) have entered into a research agreement aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of n...
Deals and Financings Suzhou Innovent Bio (IVBIY) [HK:01801] expanded its 2015 alliance with Eli Lilly (LLY) for Tyvyt ® , Innovent's anti-PD-1 immunotherapy (see story ). In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets. Lil...
News, Short Squeeze, Breakout and More Instantly...
Ascletis Pharma Inc. Company Name:
ASCLF Stock Symbol:
OTCMKTS Market:
The outbreak of the novel coronavirus disease COVID-19 rapidly spreads around the globe. The various biotechnology firms, scientists, and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective...